Legion Partners, L.P. I 4

What Happened
Christopher S. Kiper, a director of Lifecore Biomedical, Inc. and Managing Director of Legion Partners Asset Management, was granted 25,907 restricted stock units (RSUs) on June 4, 2026. The award is reported as an "A" (award/grant) on the Form 4; no per-share price or cash value is reported (N/A). These RSUs convert 1-for-1 into Lifecore common stock and vest on the earlier of June 4, 2027 or the issuer's 2027 annual meeting (with a minimum ~50-week delay). This is a grant/award (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-08 (appears timely).
• Security: Restricted Stock Units (RSUs) that convert 1-for-1 into common stock (footnote F2).
• Amount granted: 25,907 RSUs; price per share/value: N/A (award).
• Vesting: Earlier of June 4, 2027 or the 2027 annual meeting of stockholders, subject to the stated timing condition (footnote F3).
• Previously vested: 58,069 RSUs had already vested as of the filing (footnote F4).
• Ownership/beneficial interest: The RSUs are held for the benefit of Legion Partners Asset Management; Kiper disclaims personal beneficial ownership except to the extent of any indirect interests through Legion Partners entities (footnotes F4–F9). The Form 4 is filed jointly by multiple Legion Partners entities and reporting persons (footnote F1).
• Transaction code: A = Award/Grant.

Context
This is a board-service RSU grant rather than a personal open‑market purchase or sale. The award is held for the benefit of Legion Partners Asset Management and, through entity relationships, may be attributed to several Legion Partners reporting persons; Kiper serves on the board as a representative of Legion Partners. Grants to directors are routine compensation for service and do not by themselves indicate a personal trading decision.